Gemina Laboratories Ltd.
GLABF · OTC
7/31/2025 | 4/30/2025 | 1/31/2025 | 10/31/2024 | |
|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 |
| % Growth | -100% | – | – | – |
| Cost of Goods Sold | $0 | $0 | $0 | $0 |
| Gross Profit | -$0 | $0 | $0 | $0 |
| % Margin | – | 100% | – | – |
| R&D Expenses | $0 | $0 | $0 | $0 |
| G&A Expenses | $0 | $0 | $1 | $0 |
| SG&A Expenses | $0 | $0 | $1 | $0 |
| Sales & Mktg Exp. | $0 | $0 | $0 | $0 |
| Other Operating Expenses | $0 | $0 | $0 | $0 |
| Operating Expenses | $0 | $1 | $1 | $1 |
| Operating Income | -$0 | -$1 | -$1 | -$1 |
| % Margin | – | -6,367.3% | – | – |
| Other Income/Exp. Net | $0 | -$0 | -$0 | -$0 |
| Pre-Tax Income | -$0 | -$1 | -$1 | -$1 |
| Tax Expense | $0 | $0 | $0 | $0 |
| Net Income | -$0 | -$1 | -$1 | -$1 |
| % Margin | – | -6,994.2% | – | – |
| EPS | -0.004 | -0.01 | -0.019 | -0.012 |
| % Growth | 62.5% | 46.4% | -64.4% | – |
| EPS Diluted | -0.004 | -0.01 | -0.019 | -0.012 |
| Weighted Avg Shares Out | 77 | 73 | 73 | 73 |
| Weighted Avg Shares Out Dil | 77 | 73 | 73 | 73 |
| Supplemental Information | – | – | – | – |
| Interest Income | $0 | $0 | $0 | $0 |
| Interest Expense | $0 | $0 | $0 | $0 |
| Depreciation & Amortization | $0 | $0 | $0 | $0 |
| EBITDA | -$0 | -$1 | -$1 | -$1 |
| % Margin | – | -6,358.2% | – | – |